New approaches to preventing xerostomia.
D004999:Amifostine / Q000627:therapeutic use; D019610:Cytoprotection; D006801:Humans; D018721:Muscarinic Agonists / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy; D010862:Pilocarpine / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use; D011832:Radiation Injuries / Q000503:physiopathology / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012469:Salivary Glands / Q000503:physiopathology / Q000528:radiation effects; D013876:Thiophenes / Q000627:therapeutic use; D014987:Xerostomia / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*
D018721:Muscarinic Agonists; D011812:Quinuclidines; D011837:Radiation-Protective Agents; D013876:Thiophenes; D010862:Pilocarpine; C059240:cevimeline; D004999:Amifostine